IngentaConnect New Technologies for Drug Delivery Across the Blood Brain Barrier

Authors: Kabanov, A. V.¹; Batrakova, E. V.¹

Source: Current Pharmaceutical Design, Volume 10, Number 12, May 2004 , pp. 1355-1363(9)

Publisher: Bentham Science Publishers

Abstract:

The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.

Keywords: blood-brain barrier; drug efflux; drug delivery; fatty acylation; nanoge; nanoparticles; pluronic block copolymers; poloxamer

Document Type: Review article

DOI: 10.2174/1381612043384826

Affiliations: 1: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha NE 68198-6025, USA.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy